title: Disease control and toxicity outcomes using ruthenium eye plaque brachytherapy in the treatment of uveal melanoma.
abstract: OBJECTIVE
  Ruthenium-106 ((106)Ru) eye plaques have the potential to achieve excellent tumor control with acceptable radiation toxicity. We evaluated our experience in the management of uveal melanoma treated with (106)Ru brachytherapy.
  
  
  METHODS
  The records of 40 patients with uveal melanoma treated with brachytherapy using (106)Ru plaques from 2003 to 2007 at University of Texas MD Anderson Cancer Center were reviewed. Endpoints assessed included tumor control and toxicity.
  
  
  RESULTS
  Median ophthalmologic follow-up was 67 months. Actuarial 5-year rates of local control (LC), progression-free survival (PFS), and overall survival (OS) were 97%, 94%, and 92%. There were 3 deaths, 2 related to melanoma. Fifteen patients experienced clinically significant visual loss; no patients were diagnosed with neovascular glaucoma, and 1 patient developed a clinically significant radiation-associated cataract. No patient required enucleation.
  
  
  CONCLUSIONS
  We report the largest published US cohort of patients treated with (106)Ru plaque brachytherapy for uveal melanoma. Tumor control was excellent, and toxicity was acceptably low. These data support the reintroduction of (106)Ru into clinical practice for ocular melanoma.
authors.affiliation: Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Vinita
authors.initials: V
authors.lastname: Takiar
authors.affiliation: Department of Ophthalmology, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Dan S
authors.initials: DS
authors.lastname: Gombos
authors.affiliation: Department of Radiation Oncology, Christiana Care Health System, Helen F. Graham Cancer Center, Wilmington, Delaware and Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Firas
authors.initials: F
authors.lastname: Mourtada
authors.affiliation: Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Rechner
authors.affiliation: Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Ann A
authors.initials: AA
authors.lastname: Lawyer
authors.affiliation: Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: William H
authors.initials: WH
authors.lastname: Morrison
authors.affiliation: Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
authors.forename: Adam S
authors.initials: AS
authors.lastname: Garden
authors.affiliation: Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: bbeadle@mdanderson.org.
authors.forename: Beth M
authors.initials: BM
authors.lastname: Beadle
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000453:epidemiology / Q000532:radiotherapy*; D008875:Middle Aged; D012189:Retrospective Studies; D012429:Ruthenium Radioisotopes / Q000009:adverse effects* / Q000627:therapeutic use*; D014604:Uveal Neoplasms / Q000453:epidemiology / Q000532:radiotherapy*; D000098943:Uveal Melanoma
chemical_list: D012429:Ruthenium Radioisotopes